2/17
04:39 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/17
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
2/17
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
2/15
07:12 pm
jazz
Is Jazz Pharmaceuticals (JAZZ) Pricing Misaligned With DCF And Sales-Based Valuation Signals? [Yahoo! Finance]
Low
Report
Is Jazz Pharmaceuticals (JAZZ) Pricing Misaligned With DCF And Sales-Based Valuation Signals? [Yahoo! Finance]
2/14
07:09 pm
jazz
Jazz Pharmaceuticals CEO Sets Long Term Vision For Growth And Execution [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals CEO Sets Long Term Vision For Growth And Execution [Yahoo! Finance]
2/10
04:33 pm
jazz
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 [Yahoo! Finance]
2/10
04:15 pm
jazz
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Low
Report
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
2/10
04:15 pm
jazz
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Low
Report
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
2/10
01:27 am
jazz
Columbia Disciplined Value Fund Q4 2025 Commentary [Seeking Alpha]
Low
Report
Columbia Disciplined Value Fund Q4 2025 Commentary [Seeking Alpha]
2/3
07:13 am
jazz
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial [Yahoo! Finance]
Low
Report
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial [Yahoo! Finance]
1/31
03:52 pm
jazz
Is Jazz Pharmaceuticals (JAZZ) Offering An Opportunity After Recent Share Price Pullback [Yahoo! Finance]
Medium
Report
Is Jazz Pharmaceuticals (JAZZ) Offering An Opportunity After Recent Share Price Pullback [Yahoo! Finance]
1/29
10:59 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "buy" rating reaffirmed by analysts at TD Cowen.
1/18
11:53 am
jazz
Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration [Yahoo! Finance]
1/13
08:01 am
jazz
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham [Yahoo! Finance]
1/12
11:50 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.
1/12
08:04 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.
Medium
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.
1/11
08:11 am
jazz
Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain [Yahoo! Finance]
Low
Report
Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain [Yahoo! Finance]
1/10
07:35 pm
jazz
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness [Yahoo! Finance]
Low
Report
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness [Yahoo! Finance]
1/9
02:03 pm
jazz
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology [Seeking Alpha]
Low
Report
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology [Seeking Alpha]
1/8
04:37 pm
jazz
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer [Yahoo! Finance]
1/8
04:05 pm
jazz
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Low
Report
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
1/8
08:02 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/6
02:03 pm
jazz
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit [Yahoo! Finance]
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit [Yahoo! Finance]
1/6
02:01 pm
jazz
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA [Yahoo! Finance]
Low
Report
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA [Yahoo! Finance]
1/6
01:32 pm
jazz
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit